Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine, Oral Decitabine/Cedazuridine, and Venetoclax in R/R AML
NCT07814339Phase 1Not yet recruiting
- Sponsor
- Rutgers University
- Start
- Sep 2026
- Primary completion
- Jun 2028
01
Overview
Phase 1, open-label, single-arm trial of hydroxychloroquine in acute myeloid leukemia (AML), sponsored by Rutgers University. Primary endpoints: Maximum Tolerated Dose at 12 months and Recommended Phase II Dose at 12 months. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
hydroxychloroquine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07814339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07814339.